Search Results

You are looking at 21 - 30 of 188 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Shantanu Tyagi, Arandam Roy, Ravimohan Mavuduru, Girdhar Bora, Tushar Aditya Narain, and Arup Kumar Mandal

node dissection, and its extent. Postoperative variables included complications following the surgery (Clavien-Dindo classification), hospital stay, time of indwelling catheter. Follow-up data included serum PSA levels, status of urinary continence

Full access

Brian Badgwell

lymph node dissection based on the CLASSIC and ARTIST trials. 1 , 16 , 17 In the CLASSIC trial, patients in South Korea, China, and Taiwan who had undergone gastrectomy were then randomized to capecitabine plus oxaliplatin for 8 cycles versus no

Full access

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino

malignancy.” Teratomas with somatic transformation are managed somewhat differently from other nonseminomatous GCTs. For example, stage I transformed teratoma is preferentially managed with retroperitoneal lymph node dissection (RPLND) whereas other stage I

Full access

Steven G. Waguespack and Gary Francis

cervical lymph node involvement. Lymph Node Dissection Lymph node dissection reduces recurrence risk for children with PTC and improves progression-free survival. 69 , 70 The extent of lymph node dissection is based on the type and clinical

Full access

Presenters: Benjamin O. Anderson and Janice A. Lyons

subsets of patients. The appropriate uses of complete axillary lymph node dissection (cALND) and sentinel lymph node biopsy (SLNB) were discussed at the NCCN 2020 Virtual Annual Conference by Benjamin O. Anderson, MD, Professor of Surgery and Global Health

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

lesion. Sentinel Lymph Node Biopsy SLNB is a minimally invasive staging procedure developed to identify patients with subclinical nodal metastases at higher risk of recurrence who could be candidates for complete lymph node dissection or adjuvant

Full access

Ania Syrowatka, James A. Hanley, Daniala L. Weir, William G. Dixon, Ari N. Meguerditchian, and Robyn Tamblyn

-onset psychological distress during both hospital-based treatment and transitional Table 1. Sociodemographic Information, Breast Cancer Characteristics, and Treatments Received (N=16,495) survivorship included younger age, receipt of axillary lymph node

Full access

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

. Extent of groin dissection for melanoma . Surg Clin North Am 1992 ; 1 : 271 – 280 . 66 Coit DG Brennan MF . Extent of lymph node dissection in melanoma of the trunk or lower extremity . Arch Surg 1989 ; 124 : 162 – 166 . 67

Full access

Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison

consult with recurrent or metastatic disease (n=143), satellite or in-transit metastasis only (AJCC N2c nodal stage; n=4), unknown recurrence status (n=99), unclear treatment records (n=17), or <12 months follow-up from the time of lymph node dissection

Full access

Frank Qian Zhan, Vathani Sharon Packianathan, and Nathalie Charlotte Zeitouni

Merkel cell carcinoma (MCC) is a rare but aggressive cutaneous malignancy of neuroendocrine origin. Its incidence has tripled over the past 15 years. This article reviews the recent advancement in diagnosis, discoveries in pathogenesis, and updates in management. The acronym, AEIOU, has been proposed to aid in clinical identification. In addition to cytokeratin 20, newer immunohistochemical stains (in particular thyroid transcription factor-1 and neurofilament protein) have proven to be essential in pathologic diagnosis. Although immune suppression and ultraviolet radiation have long been associated with the MCC oncogenesis, recent studies also show involvement of a new polyomavirus and bcl-2. Several tumor classifications have been published in the literature, with the 4-tiered system from Memorial Sloan-Kettering Cancer Center the most widely used. A similar classification with additional distinctions among nodal disease is being constructed. A multidisciplinary treatment algorithm is recommended for MCC. Surgical excision with adjuvant radiotherapy (RT) is indicated for localized tumors. RT is favored over complete lymph node dissection and chemotherapy for regional lymph node involvement. For distant metastasis, management should be individualized with a combination of palliative surgery, RT, and chemotherapy.